DGAP-News: APONTIS PHARMA AG
/ Key word(s): Quarterly / Interim Statement
APONTIS PHARMA AG Trading Update:
Monheim am Rhein, 20 May 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, achieved revenue growth of 18% to EUR 15.1 million in the first four months from January to the end of April 2021. Growth was driven by strong demand for Single Pills, particularly for the most recently self-developed combinations Atorimib (cholesterol-lowering agent) and Tonotec HCT (antihypertensive agent). Revenues from Single Pills increased by 59% to EUR 8.9 million and accounted for 59% of APONTIS PHARMA's total revenues (Jan. - Apr. 2020: 44%). Earnings before interest, taxes, depreciation and amortization (EBITDA) increased by EUR 2.2 million to EUR 1.6 million (Jan. - Apr. 2020: negative). With an EBITDA margin of around 10%, APONTIS PHARMA is thus well on track to achieve its long-term target and is also in line with the forecast for the current financial year communicated in connection with the IPO.
APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.
20.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||APONTIS PHARMA AG|
|Listed:||Regulated Unofficial Market in Frankfurt (Scale)|
|EQS News ID:||1198571|
|End of News||DGAP News Service|